Published in Am J Hypertens on March 01, 2010
Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens (2009) 2.52
Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation (2005) 4.17
Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab (2004) 2.93
Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care (2009) 2.83
Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke (2005) 2.24
Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care (2010) 1.61
Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care (2010) 1.60
Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr (2004) 1.57
Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab (2012) 1.55
An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab (2010) 1.48
Acute modulation of toll-like receptors by insulin. Diabetes Care (2008) 1.46
Orange juice or fructose intake does not induce oxidative and inflammatory response. Diabetes Care (2007) 1.46
Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol (2009) 1.43
Rosiglitazone, thiazolidinediones and atherosclerosis. Atherosclerosis (2010) 1.41
Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract (2007) 1.35
A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab (2011) 1.35
Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab (2004) 1.34
Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol (2006) 1.23
Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care (2006) 1.18
Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care (2003) 1.16
Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol (2011) 1.15
Testosterone concentration in young patients with diabetes. Diabetes Care (2008) 1.11
Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care (2006) 1.11
Insulin infusion in acute illness. J Clin Invest (2005) 1.10
Anti-inflammatory effects of insulin. Curr Opin Clin Nutr Metab Care (2007) 1.10
The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J Clin Endocrinol Metab (2003) 1.08
Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab (2006) 1.04
Suppressive effect of insulin infusion on chemokines and chemokine receptors. Diabetes Care (2010) 1.03
Endothelial dysfunction, inflammation and diabetes. Rev Endocr Metab Disord (2004) 1.03
Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations. Endocr Pract (2011) 1.01
Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr Mol Med (2008) 1.00
Macronutrient intake induces oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistance. Exp Mol Med (2010) 0.96
Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes. Diabetes Care (2011) 0.93
Insulin suppresses endotoxin-induced oxidative, nitrosative, and inflammatory stress in humans. Diabetes Care (2010) 0.92
Proinflammatory and prothrombotic effects of hypoglycemia. Diabetes Care (2010) 0.91
The effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients. Diabetes Care (2007) 0.91
Endothelial dysfunction and hypertension in diabetes mellitus. Med Clin North Am (2004) 0.89
Insulin suppresses the expression of amyloid precursor protein, presenilins, and glycogen synthase kinase-3beta in peripheral blood mononuclear cells. J Clin Endocrinol Metab (2011) 0.88
Increase in the mediators of asthma in obesity and obesity with type 2 diabetes: reduction with weight loss. Obesity (Silver Spring) (2013) 0.87
Anti-inflammatory effects of insulin and the pro-inflammatory effects of glucose. Semin Thorac Cardiovasc Surg (2006) 0.86
Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors. Endocr Pract (2012) 0.84
Effect of hyperglycemia and insulin in acute coronary syndromes. Am J Cardiol (2007) 0.83
Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes. J Diabetes Complications (2008) 0.82
Insulin infusion suppresses while glucose infusion induces Toll-like receptors and high-mobility group-B1 protein expression in mononuclear cells of type 1 diabetes patients. Am J Physiol Endocrinol Metab (2013) 0.82
A novel view of metabolic syndrome. Metab Syndr Relat Disord (2004) 0.81
Relationship of prostate-specific antigen to age and testosterone in men with type 2 diabetes mellitus. Endocr Pract (2008) 0.81
Acute myocardial infarction, hyperglycemia, and insulin. J Am Coll Cardiol (2009) 0.81
Anti-inflammatory effects of insulin and pro-inflammatory effects of glucose: relevance to the management of acute myocardial infarction and other acute coronary syndromes. Rev Cardiovasc Med (2006) 0.80
Hypogonadotropic hypogonadism in men with type 2 diabetes. Postgrad Med (2009) 0.79
Oxidative stress and inflammation in hyperglycemic crises and resolution with insulin: implications for the acute and chronic complications of hyperglycemia. J Diabetes Complications (2012) 0.79
Use of insulin to improve glycemic control in diabetes mellitus. Cardiovasc Drugs Ther (2008) 0.78
Vascular reactivity and thiazolidinediones. Am J Med (2003) 0.77
Insulin infusion and hypoglycemia: clinical implications and prevention. Crit Care Med (2010) 0.76
Hyperglycemia synergizes endotoxin-induced injury in the heart: reversal with insulin. Crit Care Med (2009) 0.75
Glucose-insulin-potassium for suspected acute myocardial infarction. JAMA (2012) 0.75
ADJUNCT THERAPIES IN TYPE 1 DIABETES. Endocr Pract (2016) 0.75
Glucose-insulin-potassium therapy in patients with STEMI. JAMA (2008) 0.75
Associations between dietary fiber and inflammation, hepatic function, and risk of type 2 diabetes in older men: potential mechanisms for the benefits of fiber on diabetes risk: response to wannamethee et Al. Diabetes Care (2010) 0.75
Letter by Chaudhuri et al regarding article, "Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction". Circulation (2010) 0.75
Insulin therapy and lipid overload in type 2 diabetes. JAMA (2008) 0.75
Comment on: Calleja et al. insulin resistance is associated with a poor response to intravenous thrombolysis in acute ischemic stroke. Diabetes Care 2011;34:2413-2417. Diabetes Care (2012) 0.75
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes Care (2013) 0.75
Exogenous insulin and hypoglycemia as prognostic factors in critically ill patients. JAMA (2004) 0.75
An inflammatory tale from 3 fatty depots. J Am Coll Cardiol (2011) 0.75
Macronutrients, advanced glycation end products, and vascular reactivity. Diabetes Care (2007) 0.75
Glycaemic control and macrovascular complications of type 2 diabetes. Natl Med J India (2009) 0.75
Classical Anti-oxidants (Scavengers) versus Biological Anti-oxidants (Suppressors of ROS Generation): ANovel Way to Explain the Anti-oxidant Paradox. Metab Syndr Relat Disord (2004) 0.75
Are thiazolidinediones associated with an increased risk of heart failure and cardiovascular death? Nat Clin Pract Cardiovasc Med (2008) 0.75